Brief: Agenus Prioritizes Resources To Accelerate Registration And Commercialization Of Bot/Bal Program In Multiple Cancers
Aug 23 (Reuters) -
* AGENUS PRIORITIZES RESOURCES TO ACCELERATE REGISTRATION
AND
COMMERCIALIZATION OF BOT/BAL PROGRAM IN MULTIPLE CANCERS
* AGENUS INC - STRATEGIC PRIORITIZATION TO DELIVER SAVINGS
OF $40M
THROUGH END OF 2023
* AGENUS INC - PLAN WILL RESULT IN A WORKFORCE REDUCTION OF
APPROXIMATELY 25%
* AGENUS INC - UNDER THIS NEW PLAN, AGENUS WILL TEMPORARILY
POSTPONE ALL PRECLINICAL AND CLINICAL PROGRAMS NOT RELATED TO
BOT/BAL
* AGENUS INC - AGENUS' PARTNER-FUNDED PROGRAMS WILL NOT BE
AFFECTED BY THESE MEASURES
Source text for Eikon: ID:nBw6tNpkDa
Further company coverage: AGEN.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Agenus
See all newsBrief: Agenus Reports 72% Of Patients With Locally Advanced Dmmr Colon Cancer Had No Cancer Remaining At Surgery Following Six Weeks Of Bot+Bal In Phase 2 Neoasis Study At Esmo 2026
Brief: Armenia Grants First Marketing Authorizations For Agenus’ Bot+Bal In Previously Treated Mss Metastatic Colorectal Cancer
Brief: Agenus - Unit Enters Second Loan Modification Agreement With Ocean 1181 On Aug 12, 2026 - SEC Filing
Agenus Inc reports results for the quarter ended June 30 - Earnings Summary
Agenus Q2 revenue rises on access and royalty income